MedPath

Simplified Meal Approach Using Hybrid Closed-loop Insulin Delivery in Youth and Young Adults With Type 1 Diabetes

Not Applicable
Completed
Conditions
Type 1 Diabetes
Interventions
Device: SMA bolus option
Device: Exactly estimated carbohydrate content bolus option
Registration Number
NCT05481034
Lead Sponsor
Lia Bally
Brief Summary

The purpose of the study is to examine whether a simplified meal approach (as compared to exact carbohydrate counting) can alleviate the need of carbohydrate counting without worsening postprandial control in youth and young adults with type 1 diabetes using hybrid closed-loop insulin delivery with the Cambridge Artificial Pancreas FX System (CamAPS FX system).

Detailed Description

Optimal glycaemic control is the aim of diabetes care and critical in the prevention of diabetes-related complications. Despite advances in diabetes technologies and medications, many current youth and young adults (YYA) with type 1 diabetes (T1D) are not meeting desired glycaemic targets, representing a missed opportunity for improving lifetime outcomes.

A variety of factors including peer group influences, importance of body image, less parental oversight, greater risk-taking, and performance pressure challenge daily self-management in YYA with T1D. Disengagement from care and barriers for optimal glycaemic management in YYA have been mainly shown to be substantially influenced by perceived burden of daily tasks.

Although the recently introduced closed-loop systems, which link insulin delivery to sensor glucose levels, offer promising opportunities to improve glucose control in YYA with T1D, they still require the user to estimate carbohydrates. The perceived burden of exact carbohydrate counting (ECC), the limited evidence supporting its glycaemic benefit and corrective potential of algorithm-driven background insulin titration question its necessity during hybrid-closed loop insulin treatment. Instead, a simplified meal approach (SMA), which only requires the user to select the meal carbohydrate category (small/medium/large), has the potential to alleviate the burden of ECC during hybrid closed-loop insulin therapy whilst resulting in similar glycaemic benefits.

The investigators therefore hypothesize that a simplified meal approach (SMA) using the CamAPS FX system would achieve comparable glucose control compared with the use of the CamAPS FX system with ECC in YYA with T1D.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
46
Inclusion Criteria
  • Written informed consent
  • Type 1 diabetes as defined by the World Health Organization for at least 6 months
  • Age between 12 and 20 years (inclusive)
  • Proficient use of continuous glucose monitoring (CGM) or flash glucose monitoring (FGM) for at least 5 days in the past
  • Glycated hemoglobin A1c (HbA1c) ≤12%
  • The participant is willing to wear closed-loop devices
  • The participant is willing to follow study specific instructions
  • Negative urine-pregnancy test in sexually active female participants of childbearing potential at screening-visit
Exclusion Criteria
  • Any physical or psychological disease or condition likely to interfere with the normal conduct of the study and interpretation of the study results
  • Known or suspected allergy against insulin
  • Participant is pregnant or breast feeding or planning pregnancy within next 6.5 months
  • Severe visual impairment
  • Severe hearing impairment
  • Lack of reliable telephone facility for contact
  • Concomitant participation in another trial that interferes with the normal conduct of the study and interpretation of the study results
  • Participant not proficient in German

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Simplified carbohydrate estimation first, exact carbohydrate estimation secondSMA bolus optionIn the first study period, participants will use the CamAPS FX system and adopt the "simplified meal announcement" (SMA) option to bolus for their meals. SMA comprises the selection of predefined carbohydrate quantities for meal insulin dosing. Meal carbohydrate contents will be set on an individual basis at the baseline visit. In the second study period, Participants will use the CamAPS FX system and insert the estimated grams of carbohydrates into the application as exactly as possible in order to bolus for their meals.
Simplified carbohydrate estimation first, exact carbohydrate estimation secondExactly estimated carbohydrate content bolus optionIn the first study period, participants will use the CamAPS FX system and adopt the "simplified meal announcement" (SMA) option to bolus for their meals. SMA comprises the selection of predefined carbohydrate quantities for meal insulin dosing. Meal carbohydrate contents will be set on an individual basis at the baseline visit. In the second study period, Participants will use the CamAPS FX system and insert the estimated grams of carbohydrates into the application as exactly as possible in order to bolus for their meals.
Exact carbohydrate estimation first, simplified carbohydrate estimation second.SMA bolus optionIn the first study period, participants will use the CamAPS FX system and insert the estimated grams of carbohydrates into the application as exactly as possible in order to bolus for their meals. In the second study period, participants will use the CamAPS FX system and adopt the "simplified meal announcement" (SMA) option to bolus for their meals. SMA comprises the selection of predefined carbohydrate quantities for meal insulin dosing. Meal carbohydrate contents will be set on an individual basis at the baseline visit.
Exact carbohydrate estimation first, simplified carbohydrate estimation second.Exactly estimated carbohydrate content bolus optionIn the first study period, participants will use the CamAPS FX system and insert the estimated grams of carbohydrates into the application as exactly as possible in order to bolus for their meals. In the second study period, participants will use the CamAPS FX system and adopt the "simplified meal announcement" (SMA) option to bolus for their meals. SMA comprises the selection of predefined carbohydrate quantities for meal insulin dosing. Meal carbohydrate contents will be set on an individual basis at the baseline visit.
Primary Outcome Measures
NameTimeMethod
Percentage of time with sensor glucose measurements between 3.9 and 10.0 mmol/LFrom the first day of the respective study period to 3 months thereafter

The percentage of time with sensor glucose measurements between 3.9 and 10.0 mmol/L will be compared between both intervention arms. Primary analysis will be carried out according to a non-inferiority framework.

Secondary Outcome Measures
NameTimeMethod
Time spent with sensor glucose measurements < 3.9 mmol/LFrom the first day of the respective study period to 3 months thereafter

The percentage of time with sensor glucose measurements \< 3.9 mmol/L (%)

Time spent with sensor glucose values above target (>10.0 mmol/L)From the first day of the respective study period to 3 months thereafter

Percentage of time spent with sensor glucose values above target (\>10.0 mmol/L)

Mean peak postprandial glucoseFrom the first day of the respective study period to 3 months thereafter

Mean peak postprandial glucose (mmol/L) assessed within 180min following main meals (defined as carbohydrate amounts \>25g entered into the CamAPS app by the participants).

Number of clinically significant hypoglycaemia (number of events with sensor glucose <3.9 mmol/L for at least 15min)From the first day of the respective study period to 3 months thereafter

Number of events with sensor glucose \<3.9 mmol/L for at least 15min

Time spent with sensor glucose values >13.9 mmol/L (%)From the first day of the respective study period to 3 months thereafter

Percentage of time spent with sensor glucose values \>13.9 mmol/L (%)

Extended hypoglycaemia event rate (number of events with sensor glucose <3.9 mmol/L lasting at least 120min)From the first day of the respective study period to 3 months thereafter

Number of events with sensor glucose \<3.9 mmol/L lasting at least 120min

Time spent with sensor glucose measurements < 3.0 mmol/LFrom the first day of the respective study period to 3 months thereafter

The percentage of time with sensor glucose measurements \< 3.0 mmol/L (%)

Time spent with sensor glucose measurements between < 3.9 mmol/L and 7.8 mmol/L (%)From the first day of the respective study period to 3 months thereafter

The percentage of time with sensor glucose between \< 3.9 mmol/L and 7.8 mmol/L (%)

Mean sensor glucose level (mmol/L)From the first day of the respective study period to 3 months thereafter

Mean of all sensor glucose levels (mmol/L)

HbA1cAt baseline and at the predefined study visits (3 months after the start of the respective periods)

Glycated hemoglobin A1c (%)

Coefficient of sensor glucose variation (%)From the first day of the respective study period to 3 months thereafter

Coefficient of sensor glucose variation (%)

Standard deviation of sensor glucose variation (mmol/L)From the first day of the respective study period to 3 months thereafter

Standard deviation of sensor glucose variation (mmol/L)

Glucose Management Indicator (%)From the first day of the respective study period to 3 months thereafter

Glucose Management Indicator (%)

Extended hyperglycaemia event rate (number of events with sensor glucose >13.9 mmol/L lasting at least 120min)From the first day of the respective study period to 3 months thereafter

Number of events with sensor glucose \>13.9 mmol/L lasting at least 120min

Proportion of participants with sensor glucose in the target range (3.9 - 10.0 mmol/L for >70% of the time.From the first day of the respective study period to 3 months thereafter

Proportion of participants with sensor glucose in the target range (3.9 - 10.0 mmol/L for \>70% of the time.

Trial Locations

Locations (2)

Department of Paediatric Endocrinology and Diabetes, University Children's Hospital Zurich

🇨🇭

Zürich, Switzerland

Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland

🇨🇭

Bern, Switzerland

© Copyright 2025. All Rights Reserved by MedPath